VGN Bio, Inc. is developing new anti-cancer drugs by increasing the efficacies of existing antibody agents. Our research program is based on over 20 years of virology research at the University of California Davis. Viruses require host cells for their replication and have evolved unique strategies to hijack cellular protein function through millions of years of viral-host co-evolution. The goal of VGN BIO is to leverage the knowledge of virus-host interactions to design novel inhibitors and develop these into innovative drugs.